Previous Close | 13.740 |
Open | 13.720 |
Bid | 14.500 x 0 |
Ask | 14.520 x 0 |
Day's Range | 13.220 - 14.600 |
52 Week Range | 12.420 - 52.450 |
Volume | |
Avg. Volume | 58,225,071 |
Market Cap | 60.442B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | 17.49 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today published its 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's substantial progress in advancing sustainable development.
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.